Roche's Genentech spends $15M to rocket into GenEdit’s NanoGalaxy

The next wave of gene editing advances will likely center not only on efficacy but on the diversity of where the therapies can be delivered, and Genentech is signing a new deal to keep up with the competition.

The Roche unit is paying $15 million and offering $629 million in biobucks to use GenEdit’s polymer nanoparticle-based platform to develop gene therapies for autoimmune diseases.